The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Sustained safety and efficacy of the magnesium scaffold: does the Magmaris scaffold call for the return of BRS research… and randomised controlled trials?

EuroIntervention 2020;15:e1307-e1311. DOI: 10.4244/EIJV15I15A238

1. National University of Ireland, Galway, Ireland; 2. Imperial College London, London, United Kingdom


Concept and design of a bioresorbable scaffold, which “does its job and disappears”

A fully bioresorbable scaffold (BRS) should be viewed as a transient coronary implantation device which prevents acute recoil and constrictive remodelling for a limited duration of time, elutes an antiproliferative drug to avoid excessive neointimal hyperplasia and then disappears by biodegradation (“does its job and disappears”)1. Since the peak of chronic vascular constriction and neointima hyperplasia occurs approximately three to six months after balloon angioplasty and/or bare metal stenting2,3,4, a BRS providing mechanical support for three to six months with ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Haemodynamic support for cardiogenic shock and high-risk PCI: what can observational data tell us?